Abstract
A number of characteristics of antipsychotic medications have inspired a search for early predictors of drug response. Unless a clinician has a well-documented history that a patient will respond to a particular drug or drug dose, treatment decisions will usually be made on a trial and error basis. After a decision is made to begin a trial of a particular regimen, the clinician and patient will often have to wait for weeks or even months before it is established that the treatment is successful. Moreover, if the patient fails to respond to an adequate trial of a particular drug, the clinician may be unsure if the drug was an effective one that was administered at too high or too low a dose. For these reasons, researchers have searched for pharmacokinetic indicators which can guide pharmacotherapy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bigelow LB, Kirch DG, Braun T, Korpi BT (1985) Absence of relationship of serum haloperidol concentration and clinical response in chronic schizophrenia: a fixed-dose study. Psychopharmacol Bull 21:66–68.
Bleeker JAC, Dingemans PM, Frohn-De Winder ML (1984) Plasma level and effect of low-dose haloperidol in acute psychosis. Psychopharmacol Bull 20:317–319.
Cohen BM, Waternaux C (1993) Neuroleptic plasma levels: limitations and values. In: Marder SR, Davis JM, Janicak PG (eds) Clinical use of neuroleptic plasma levels. American Psychiatric Press, Washington DC London, pp 1–15.
Cohen BM, Zubenko GS (1985) Relevance of genetic variability to clinical psychopharmacology. Psychopharmacol Bull 21:641–650.
Creese I, Burt DR, Snyder SH (1976) Dopamine receptor binding predicts clinical and pharmacologic potencies of antischizophrenic drugs. Science 192:481–483.
Dysken MW, Javaid JI, Chang SS et al. (1981) Fluphenazine pharmacokinetics and therapeutic response. Psychopharmacol (Berl) 73:205–210.
Farde L, Nordstrom A-L, Wiesel FA et al. (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry 49:538–544.
Hitzemann RJ, Garver DL, Mavroidis M et al. (1986) Fluphenazine activity and antipsychotic response. Psychopharmacol (Berl) 90:270–273.
Itoh H, Yagi G, Fuji Y et al. (1984) The relationship between haloperidol blood levels and clinical responses. Prog Neuropsychopharmacol Biol Psychiatry 8:285–292.
Jorgensen A (1986) Metabolism and pharmacokinetics of antipsychotic drugs. In: Bridges JW, Chasseaud LF (eds) Progress in drug metabolism. Taylor and Francis, London Philadelphia, pp 111–174.
Levinson DF, Simpson GM, Lo ES, Cooper TB (1993) Fluphenazine plasma levels, dosage and acute treatment response In: Marder SR, Davis JM, Janicak PG (eds) Clinical use of neuroleptic plasma levels. American Psychiatric Press, Washington DC London, pp 45–61.
Linkowski P, Hubain P, von Frenckell R et al. (1984) Haloperidol plasma levels and clinical response in paranoid schizophrenics. Eur Arch Psychiatry Neurol Sci 234:231–236.
Marder SR, Midha KK, Van Putten T, Aravagiri M, Hawes EM, Hubbard JW, McKay G, Mintz J (1991) Plasma levels of fluphenazine in patients receiving fluphenazine decanoate: relationship to clinical response. Br J Psychiatry 158:658–665.
Marder SR, Van Putten T, Mintz J, Lebell M, McKenzie J, May PRA (1987) Low and conventional dose maintenance therapy with fluphenazine decanoate: two year outcome. Arch Gen Psychiatry 44:518–521.
Mavroidis ML, Kanter DR, Hirschozitz J et al. (1983) Clinical response and plasma haloperidol levels in schizophrenia. Psychopharmacology 81:354–356.
Mavroidis ML, Kanter DR, Hirschozitz J et al. (1984) Fluphenazine plasma levels and clinical response. J Clin Psychiatry 45:370–373.
May PRA, Van Putten T (1978) Plasma levels of chlorpromazine in schizophrenia: a critical review of the literature. Arch Gen Psychiatry 35:1081–1087.
Midha KK, Hawes EM, Hubbard JW, Korchinski ED, McKay G (1989) Intersubject variation in the pharmacokinetics of chlorpromazine in healthy men. J Clin Psychopharmacol 9:48.
Potkin SG, Shen Y, Zhou D et al. (1985) Does a therapeutic window for plasma haloperidol exist? — Preliminary Chinese data. Psychopharmacol Bull 21:59–61.
Rimon R, Averbuch I, Rozick P et al. (1981) Serum and CSF levels of haloperidol by radioimmunoassay and radioreceptor assay during high-dose therapy of resistant schizophrenic patients. Psychopharmacology 73:197–199.
Santos JL, Cabranes JA, Almoguere I (1989) Clinical implications of determination of plasma haloperidol levels. Acta Psychiatr Scand 79:348–354.
Seeman P, Lee T, Chau-Wong M, Wong K (1976) Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261:717–719.
Smith RC, Baumgartner R, Misra CH (1984) Haloperidol plasma levels and prolactin response as predictors of clinical improvement in schizophrenia: chemical vs radioreceptor plasma level assay. Arch Gen Psychiatry 41:1044–1049.
Van Putten T, Aravagiri M, Marder SR, Wirshing WC, Mintz J, Chabert N (1991a) Plasma fluphenazine levels and clinical response in newly admitted schizophrenic patients. Psy-chopharmacol Bull 27:91–96.
Van Putten T, Marder SR, Mintz J, Poland RE (1992) Haloperidol plasma levels and clinical response: a therapeutic window relationship. Am J Psychiatry 149:500–505.
Van Putten T, Marder SR, Wirshing WC, Aravagiri M, Chabert N (1991b) Neuroleptic plasma levels. Schizophr Bull 17:197–216.
Volavka J, Cooper T, Czobor P et al. (1992) Haloperidol blood levels and clinical effects. Arch Gen Psychiatry 49:354–361.
Wistedt B, Johanidesz G, Omerhodzic M et al. (1984) Plasma haloperidol levels and clinical response in acut schizophrenia. Nordisk Psychiatrik Tidsskrift 1:9–13.
Wolkin A, Brodie JD, Barouche F et al. (1989) Dopamine receptor occupancy and plasma haloperidol levels. Arch Gen Psychiatry 46:482–483.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer-Verlag Wien
About this paper
Cite this paper
Marder, S.R. (1994). Pharmacokinetic aspects of neuroleptics and prediction of outcome. In: Gaebel, W., Awad, A.G. (eds) Prediction of Neuroleptic Treatment Outcome in Schizophrenia. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6636-9_8
Download citation
DOI: https://doi.org/10.1007/978-3-7091-6636-9_8
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-82602-7
Online ISBN: 978-3-7091-6636-9
eBook Packages: Springer Book Archive